Journal of Vascular Surgery
Volume 52, Issue 3 , Pages 576-583.e2, September 2010

CAPTURE 2 risk-adjusted stroke outcome benchmarks for carotid artery stenting with distal embolic protection

  • Jon S. Matsumura, MD

      Affiliations

    • Division of Vascular Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisc
    • Corresponding Author InformationReprint requests: Jon S. Matsumura, MD, Division of Vascular Surgery, University of Wisconsin School of Medicine and Public Health, G5/325 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792
  • ,
  • William Gray, MD

      Affiliations

    • Center for Interventional Vascular Therapy, Columbia University, New York, NY
  • ,
  • Seemant Chaturvedi, MD

      Affiliations

    • Wayne State University, Detroit, Mich
  • ,
  • Xingyu Gao, MS

      Affiliations

    • Abbott Vascular, Endovascular Clinical Science, Santa Clara, Calif
  • ,
  • Jin Cheng, MD, PhD

      Affiliations

    • Abbott Vascular, Endovascular Clinical Science, Santa Clara, Calif
  • ,
  • Patrick Verta, MD

      Affiliations

    • Abbott Vascular, Endovascular Clinical Science, Santa Clara, Calif
  • ,
  • CAPTURE 2 Investigators and Executive Committee

Received 2 October 2009; accepted 25 March 2010. published online 24 June 2010.

Objective

Many medical procedures undergo rapid evolution and process of care improvements after introduction. National outcome standards are useful to help physicians, institutions, and other stakeholders evaluate the quality of their programs and take action when suboptimal outcomes are identified. The purpose of this analysis was to derive contemporary risk-adjusted stroke rates from a large, contemporary, independently assessed outcome database within 30 days after carotid artery stenting (CAS) in the United States.

Methods

The second phase of carotid ACCULINK/ACCUNET post approval trial to uncover rare events (CAPTURE 2) is an ongoing prospective, multicenter, clinical trial conducted to assess CAS outcomes in the general practice setting after device approval for high surgical risk patients (symptomatic with >50% stenosis or asymptomatic with >80% stenosis). A neurologist examined the patients before the procedure, at 1 day and 30 days after CAS. The primary endpoint was a composite of death, any stroke, or myocardial infarction (MI) within the periprocedural period. Strokes and neurologic events suspected to be strokes were adjudicated by an independent clinical events adjudication committee. Logistic regression analysis including stepwise logistic and multivariable modeling was performed to determine clinical predictors of periprocedural stroke outcome and generate a parsimonious model that could be used for a clinical standard.

Results

Five thousand two hundred ninety-seven consecutive patients (5297) had CAS performed by 459 physicians at 186 sites before the data cutoff of January 10, 2009. The 30-day rate of stroke was 2.7% (95% confidence interval [CI], 2.3–3.2). Multivariable predictors of periprocedural stroke included age, symptomatic status, and dwell time of embolic protection device. A parsimonious model Pi = 1/(1+e −(−3.83 + 0.51 × (symptomatic) + 0.31 × (age ≥80) + 0.62 × (age ≥80 × symptomatic)), including symptomatic and octogenarian status and the term of the interaction of the two, was established based on consideration of clinical predictors, clinical interaction, and practicability.

Conclusion

CAS outcomes in patients at high surgical risk have comparable periprocedural outcomes to published randomized trials of endarterectomy for patients at standard surgical risk. A model is presented for calculating a contemporary national standard for risk-adjusted stroke rates. Quality improvement measures could be based on relative performance to this benchmark and could improve overall outcomes for patients undergoing CAS.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Competition of interest: Dr Matsumura received research support, consultation fees, or training director fees from Abbott, Cook, EV3, Lumen, Medtronic, and WL Gore. Dr Cheng is an employee of sponsor for the clinical trial (Abbott), and Dr Gao and Dr Verta are employees of Abbott.

 Additional material for this article may be found online at www.jvascsurg.org.

 The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.

PII: S0741-5214(10)00811-6

doi:10.1016/j.jvs.2010.03.064

Journal of Vascular Surgery
Volume 52, Issue 3 , Pages 576-583.e2, September 2010